The cost of poor blood specimen quality and errors in preanalytical processes
The cost of poor blood specimen quality and errors in preanalytical processes
复制标题
DOI：
10.1016/j.clinbiochem.2013.06.001
复制
发表时间：
2013-09-01
影响因子：
2.8
通讯作者：
Green, Sol F.
中科院分区：
文献类型：
--
作者：
Green, Sol F.
目的：医疗差错发生率的增加是一个令人不安的趋势;医院差错是美国第八大死亡原因。对于临床实验室，在检测的预分析阶段发生的错误可能占总实验室错误的75%;其中26%可能对患者护理产生不利影响，导致不必要的检查或不适当的治疗，住院时间延长以及对医疗服务的不满。本综述重点关注这些错误，特别是在分析前阶段观察到的错误，以及它们如何影响临床和财务结果。财务后果也证明通过一个模型，估计成本的预分析错误的医院和实验室以及病人护理。(c)2013年加拿大临床化学家协会。爱思唯尔公司出版All rights reserved.
Objectives: The increase in the prevalence of medical errors represents a disturbing trend; hospital-based errors are the eighth leading cause of death in the United States. For the clinical laboratory, errors that occur in the preanalytical phase of testing may account for up to 75% of total laboratory errors; 26% of these may have detrimental effects on patient care, which contribute to unnecessary investigations or inappropriate treatment, increase in lengths of hospital stay, as well as dissatisfaction with healthcare services. This review focuses on these errors, particularly those observed in the preanalytical phase, and how they may affect clinical and financial outcomes. Financial ramifications are also demonstrated through a model that estimates the costs of preanalytical errors for the hospital and laboratory as well as patient care. (c) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.